Itch-Focused Creabilis Finally Secures Its Future Through US Sale
Creabilis has finally secured the future of its Phase III-ready psoriatic itch candidate CT327 – through a sale of the company to young US firm Sienna Biopharmaceuticals.
Creabilis has finally secured the future of its Phase III-ready psoriatic itch candidate CT327 – through a sale of the company to young US firm Sienna Biopharmaceuticals.